Reviving Europe's IPO Market: What VCs Need to Do
Professor Christopher Evans, DSc, chairman of venture firm Merlin Biosciences, identified European public market investors' continued reluctance to support biotech IPOs as a significant threat to the sector's viability during a keynote presentation at the Financial Times Global Biotech conference in London in November. Yet there's a lot more VCs themselves can do to get the sector back on its feet, acknowledges Merlin's CEO Mark Clement, including putting more money into creating stronger companies from the outset, and simplifying approaches to, and support for, M&A.
You may also be interested in...
Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.
Encouraged by successes in the biotech space, public market investors' interest in the device arena has returned in 2004 to support 10 companies' IPOs so far. Windhover's analysis of the valuations achieved indicate that private investors in these companies have, on average, enjoyed larger returns than their biotech counterparts.
Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.